Self-renewal of CD133hi cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer

Nature Communications

Volumn 7, Issue , 2016, Pages

  Sansone, Pasquale ^a   Ceccarelli, Claudio ^b   Berishaj, Marjan ^a   Chang, Qing ^a   Rajasekhar, Vinagolu K ^a   Perna, Fabiana ^a   Bowman, Robert L ^a   Vidone, Michele ^b   Daly, Laura ^a   Nnoli, Jennifer ^a   Santini, Donatella ^c   Taffurelli, Mario ^b   Shih, Natalie N C ^d   Feldman, Michael ^d   Mao, Jun J ^e   Colameco, Christopher ^e   Chen, Jinbo ^e   DeMichele, Angela ^e   Fabbri, Nicola ^a   Healey, John H ^a   Cricca, Monica ^b   Gasparre, Giuseppe ^b   Lyden, David ^a,f   Bonafé, Massimiliano ^b,c   Bromberg, Jacqueline ^a,f   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; ESTROGEN RECEPTOR; INTERLEUKIN 6; NOTCH3 RECEPTOR; ANASTROZOLE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; EXEMESTANE; FULVESTRANT; GLYCOPROTEIN; LETROZOLE; LEUKOCYTE ANTIGEN; LEUPRORELIN; NITRILE; NOTCH RECEPTOR; NOTCH3 PROTEIN, HUMAN; PEPTIDE; PROM1 PROTEIN, HUMAN; PROM1 PROTEIN, MOUSE; TAMOXIFEN; TRIAZOLE DERIVATIVE;

BIOACTIVITY; CANCER; CELLS AND CELL COMPONENTS; ENDOCRINE DISRUPTOR; GENE EXPRESSION; HORMONE; INHIBITION; METABOLISM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST METASTASIS; CANCER HORMONE THERAPY; CANCER MODEL; CANCER STEM CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL SELF-RENEWAL; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; BONE TUMOR; BREAST TUMOR; CANCER TRANSPLANTATION; CELL SELF-RENEWAL; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IN VITRO STUDY; LUNG CARCINOMA; MCF-7 CELL LINE; METABOLISM; METASTASIS; NONOBESE DIABETIC MOUSE; OXIDATIVE PHOSPHORYLATION; PAGET NIPPLE DISEASE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SCID MOUSE; SECONDARY; TUMOR CELL LINE;

AC133 ANTIGEN; ANDROSTADIENES; ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL LINE, TUMOR; CELL SELF RENEWAL; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IN VITRO TECHNIQUES; INTERLEUKIN-6; LEUPROLIDE; MCF-7 CELLS; MICE, INBRED NOD; MICE, SCID; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; NITRILES; OXIDATIVE PHOSPHORYLATION; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, NOTCH3; RECEPTORS, ESTROGEN; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TAMOXIFEN; TRIAZOLES;

EID: 84957921760     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10442     Document Type: Article

References (27)

1. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumourigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
2. Korkaya, H. et al. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell 47, 570-584 (2012).
3. Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62-73 (2010).
4. Hwang-Verslues, W. W. et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS ONE 4, e8377 (2009).
5. Shipitsin, M. et al. Molecular definition of breast tumour heterogeneity. Cancer Cell 11, 259-273 (2007).
6. Arapantoni-Dadioti, P. et al. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumours with paired metachronous recurrences or metastases. J. BUON 17, 277-283 (2012).
7. Niikura, N. et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumours. J. Clin. Oncol. 30, 593-599 (2012).
8. Toy, W. et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 45, 1439-1445 (2013).
9. Osborne, C. K. & Schiff, R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 62, 233-247 (2011).
10. Idirisinghe, P. K. et al. Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am. J. Clin. Pathol. 133, 416-429 (2010).
11. Leary, A. F. et al. Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin. Cancer Res. 16, 1486-1497 (2010).
12. Knupfer, H. & Preiss, R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 102, 129-135 (2007).
13. Nadal, R. et al. CD133 expression in circulating tumour cells from breast cancer patients: potential role in resistance to chemotherapy. Int. J. Cancer 133, 2398-2407 (2013).
14. Creighton, C. J. et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumour-initiating features. Proc. Natl Acad. Sci. USA 106, 13820-13825 (2009).
15. Wong, D. J. et al. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell 2, 333-344 (2008).
16. Ben-Porath, I. et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumours. Nat. Genet. 40, 499-507 (2008).
17. Gilani, R. A. et al. The importance of HER2 signaling in the tumour-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res. Treat. 135, 681-692 (2012).
18. Ray, A., Prefontaine, K. E. & Ray, P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. J. Biol. Chem. 269, 12940-12946 (1994).
19. Giordano, G., Gabrielli, M., Gnetti, L. & Ferri, T. Oncocytic carcinoma of parotid gland: a case report with clinical, immunohistochemical and ultrastructural features. World J. Surg. Oncol. 4, 54 (2006).
20. Rimawi, M. F. & Osborne, C. K. Breast Cancer: Blocking both driver and escape pathways improves outcomes. Nat. Rev. 9, 133-134 (2012).
21. Chang, Q. et al. The IL-6/JAK/Stat3 feed-forward loop drives tumourigenesis and metastasis. Neoplasia 15, 848-862 (2013).
22. Sansone, P. et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in human stem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 25, 807-815 (2007).
23. Creighton, C. J. A gene transcription signature associated with hormone independence in a subset of both breast and prostate cancers. BMC Genomics 8, 199 (2007).
24. Bai, R. K., Perng, C. L., Hsu, C. H. & Wong, L. J. Quantitative PCR analysis of mitochondrial DNA content in patients with mitochondrial disease. Ann. N Y Acad. Sci. 1011, 304-309 (2004).
25. Qian, W. & Van Houten, B. Alterations in bioenergetics due to changes in mitochondrial DNA copy number. Methods 51, 452-457 (2010).
26. Calabrese, C. et al. MToolBox: a highly automated pipeline for heteroplasmy annotation and prioritization analysis of human mitochondrial variants in high-throughput sequencing. Bioinformatics 30, 3115-3117 (2014).
27. Hu, Y. & Smyth, G. K. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J. Immunol. Methods 374, 70-78 (2009).